According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
Shares of Quotient (NASDAQ:QTNT) opened at 7.35 on Wednesday. The firm has a 50-day moving average of $7.36 and a 200 day moving average of $8.26. The firm’s market cap is $105.66 million. Quotient has a 52 week low of $5.67 and a 52 week high of $17.44.
In other news, Director L John Wilkerson bought 180,000 shares of the stock in a transaction dated Wednesday, August 3rd. The stock was bought at an average price of $5.50 per share, for a total transaction of $990,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider D J. Paul E. Cowan bought 45,455 shares of the stock in a transaction dated Wednesday, August 3rd. The stock was purchased at an average price of $5.50 per share, with a total value of $250,002.50. Following the acquisition, the insider now owns 26,666 shares of the company’s stock, valued at $146,663. The disclosure for this purchase can be found here. 40.50% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC purchased a new stake in shares of Quotient during the first quarter valued at approximately $105,000. First New York Securities LLC NY purchased a new stake in shares of Quotient during the second quarter valued at approximately $140,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Quotient during the first quarter valued at approximately $172,000. BlackRock Investment Management LLC increased its stake in shares of Quotient by 2.5% in the second quarter. BlackRock Investment Management LLC now owns 86,418 shares of the company’s stock valued at $670,000 after buying an additional 2,075 shares in the last quarter. Finally, Bellevue Group AG purchased a new stake in shares of Quotient during the first quarter valued at approximately $880,000. Institutional investors own 41.50% of the company’s stock.
Quotient Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quotient Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.